MNM Bioscience (2020-2022), Out-licensed technology.
Kelly Gordon, PhD, MB(ASCP)CM, RAC-Devices, Founder & CEO
Dr. Kelly Gordon founded Boudicca® DX to put world-class precision medicine expertise within reach of every developer — from first-in-class startups to global biopharma. As a dual US-Irish citizen, she leads both the US (Boudicca DX, LLC) and EU (Boudicca DX Limited) operations, bringing rare cross-continental fluency to every engagement.
Her credentials span three disciplines that rarely converge in a single expert: she is an ASCP-certified Molecular Biology Scientist and Biomarker Testing Navigator, a Pharmacology PhD-trained translational scientist, and a RAPS-certified global regulatory affairs professional (EU, US, and ROW). She meets all qualifications to serve as an EU IVDR and MDR Person Responsible for Regulatory Compliance (PRRC) under Article 15(6). Her hands-on industry career spans HTG Molecular, Kura Oncology, Loxo Oncology (now Eli Lilly), Provista Diagnostics, Roche Tissue Diagnostics (Ventana Medical Systems), and the Southern Arizona VA Molecular Diagnostics Laboratory.
Over 10 years as a consultant, Dr. Gordon has guided novel precision medicine products to global regulatory approval — including companion and complementary diagnostics, clinical diagnostics, drug development tools, digital pathology software, clinical decision support tools, SaMDs, digital imaging software, and medical devices.
Beyond client work, she has been appointed to multiple Scientific Advisory Boards, supported SBIR, STTR, and EIC grant applications, and served as an invited NIH Committee Member and Reviewer for the National Institute on Aging Special Emphasis Panel. She is also a recognized CLSI member. Dr. Gordon has authored precision medicine manuscripts working as a scientist in the field for 25+ years:
- Lourenco, A et al. A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years, Clinical Breast Cancer, 2017
- Henderson, M et al. Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer, PLoS One, 2016
- Gordon, K et al. Role of transforming growth factor-β superfamily signaling pathways in human disease, Biochimica et Biophysica Acta – Molecular Basis of Disease, 2008
- Dong, M et al. The type III TGF-beta receptor suppresses breast cancer progression, J Clin Invest, 2007
- Gordon, K et al. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis, 2009
- Gordon, K et al, Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression, Carcinogenesis, 2008
Scientific Advisory Boards
Education
- PhD in Pharmacology & Graduate Certificate in Cell and Molecular Biology
- BS magna cum laude, Molecular and Cellular Biology. Minor in Chemistry, Math & Physics.
Postdoctoral Fellowships
- Translational Oncology
- Cancer Biology
Boudicca, She who Brings “Victory”
Pronounced “boo·di·kuh”
The story behind the name
Boudicca was a Celtic warrior queen who did what no one thought possible — she united rival tribes, inspired collective action, and led a rebellion against one of the most powerful forces in the ancient world. She was fierce, strategic, and utterly decisive in the face of overwhelming odds.
Precision medicine product development demands exactly that kind of leadership. The regulatory landscape shifts constantly. Budgets are tight, timelines are tighter, and well-funded competitors are never far behind. Developers need more than a consultant — they need a strategic partner who has seen it all, moves fast, and fights for their product like it’s her own.
That partner is Boudicca® DX.
The name is also personal. Kelly — derived from the Gaelic word for “warrior” — was born in Belfast, Northern Ireland during The Troubles, a childhood shaped by resilience, complexity, and the quiet courage of people navigating extraordinary circumstances. She grew up visiting Celtic ruins on school trips, captivated by the stories of warriors who refused to surrender. At 15, she immigrated to the United States, just two years before the Good Friday Agreement brought peace to the land she left behind.
That history is woven into everything Boudicca® DX stands for: the belief that with the right strategy, the right expertise, and the right determination, you can navigate any obstacle — and come out stronger on the other side.
COO
Carlos Murrieta oversees the daily operational functions of Boudicca® DX, including information technology, human resources, and employee benefits administration (401(k), pension, cash balance, and profit sharing plans).
He brings 20+ years of operations leadership in highly regulated industries — automotive, battery development, and medical devices — with a track record of managing both small and large teams through complex, compliance-driven environments. His 10+ years of medical device instrumentation experience includes roles at Roche Tissue Diagnostics (Ventana Medical Systems), Bio-Rad, and 10X Genomics, where he contributed to instrument engineering, device regulatory documentation, and audit readiness including Instrument Qualification (IQ), Operation Qualification (OQ), and Process Qualification (PQ) procedures, calibration, preventive maintenance, and reliability testing.
Carlos holds an Associate of Applied Sciences in Electronics Engineering Technology from ITT Technical Institute (Tucson, AZ). A native of Nogales, Mexico, he is bilingual in English and Spanish — an asset that reflects the diverse, globally-minded culture at the heart of Boudicca® DX.
